CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.08
0.33%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Thu: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 3.07
Open* 3.08
1-Year Change* -4.64%
Day's Range* 3.05 - 3.09
52 wk Range 1.96-5.60
Average Volume (10 days) 282.45K
Average Volume (3 months) 9.24M
Market Cap 268.26M
P/E Ratio -100.00K
Shares Outstanding 103.58M
Revenue N/A
EPS -0.87
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 22, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 3.07 -0.03 -0.97% 3.10 3.23 3.05
Mar 26, 2024 3.05 -0.10 -3.17% 3.15 3.17 3.03
Mar 25, 2024 3.12 -0.28 -8.24% 3.40 3.40 3.11
Mar 22, 2024 3.28 -0.31 -8.64% 3.59 3.59 3.24
Mar 21, 2024 3.58 0.04 1.13% 3.54 3.63 3.54
Mar 20, 2024 3.48 -0.02 -0.57% 3.50 3.57 3.39
Mar 19, 2024 3.46 0.02 0.58% 3.44 3.58 3.41
Mar 18, 2024 3.48 0.09 2.65% 3.39 3.59 3.25
Mar 15, 2024 3.21 0.10 3.22% 3.11 3.27 3.11
Mar 14, 2024 3.14 -0.09 -2.79% 3.23 3.27 3.10
Mar 13, 2024 3.26 0.02 0.62% 3.24 3.36 3.22
Mar 12, 2024 3.28 0.18 5.81% 3.10 3.32 3.02
Mar 11, 2024 3.08 -0.19 -5.81% 3.27 3.38 3.02
Mar 8, 2024 3.34 0.01 0.30% 3.33 3.49 3.28
Mar 7, 2024 3.24 -0.09 -2.70% 3.33 3.34 3.20
Mar 6, 2024 3.34 -0.14 -4.02% 3.48 3.49 3.15
Mar 5, 2024 3.45 -0.04 -1.15% 3.49 3.58 3.34
Mar 4, 2024 3.50 0.20 6.06% 3.30 3.67 3.30
Mar 1, 2024 3.22 0.24 8.05% 2.98 3.49 2.98
Feb 29, 2024 4.31 -0.06 -1.37% 4.37 4.45 4.23

Humacyte, Inc. Events

Time (UTC) Country Event
Friday, May 10, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Humacyte Inc Earnings Release
Q1 2024 Humacyte Inc Earnings Release

Forecast

-

Previous

-
Thursday, June 6, 2024

Time (UTC)

12:00

Country

US

Event

Humacyte Inc Annual Shareholders Meeting
Humacyte Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 1.565 1.263 1.491 6.187
Revenue 1.565 1.263 1.491 6.187
Total Operating Expense 86.143 79.187 66.091 91.878
Selling/General/Admin. Expenses, Total 22.883 21.13 12.013 16.275
Research & Development 63.26 61.341 54.078 75.603
Unusual Expense (Income) 0 -3.284 0 0
Operating Income -84.578 -77.924 -64.6 -85.691
Interest Income (Expense), Net Non-Operating -3.571 -4.332 -1.924 0.269
Net Income Before Taxes -11.965 -26.477 -66.524 -85.422
Net Income After Taxes -11.965 -26.477 -66.524 -85.422
Net Income Before Extra. Items -11.965 -26.477 -66.524 -85.422
Net Income -11.965 -26.477 -66.524 -85.422
Income Available to Common Excl. Extra. Items -11.965 -26.477 -66.524 -85.422
Income Available to Common Incl. Extra. Items -11.965 -26.477 -66.524 -85.422
Diluted Net Income -11.965 -26.477 -66.524 -85.422
Diluted Weighted Average Shares 103.051 103.003 103.003 103.003
Diluted EPS Excluding Extraordinary Items -0.11611 -0.25705 -0.64584 -0.82931
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.11611 -0.28893 -0.64584 -0.82931
Other, Net 76.184 55.779
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0.031 1.301
Revenue 0 0 0 0.031 1.301
Total Operating Expense 26.045 22.512 20.79 23.525 19.832
Selling/General/Admin. Expenses, Total 6.191 5.234 5.833 6.188 5.18
Research & Development 20.54 17.278 14.957 17.337 14.652
Operating Income -26.045 -22.512 -20.79 -23.494 -18.531
Interest Income (Expense), Net Non-Operating -0.231 -0.224 -0.225 -0.758 -1.187
Other, Net 3.57 -14.233 17.295 -1.029 56.586
Net Income Before Taxes -22.706 -36.969 -3.72 -25.281 36.868
Net Income After Taxes -22.706 -36.969 -3.72 -25.281 36.868
Net Income Before Extra. Items -22.706 -36.969 -3.72 -25.281 36.868
Net Income -22.706 -36.969 -3.72 -25.281 36.868
Income Available to Common Excl. Extra. Items -22.706 -36.969 -3.72 -25.281 36.868
Income Available to Common Incl. Extra. Items -22.706 -36.969 -3.72 -25.281 36.868
Diluted Net Income -22.706 -36.969 -3.72 -25.281 36.868
Diluted Weighted Average Shares 103.362 103.264 103.163 103.032 103.908
Diluted EPS Excluding Extraordinary Items -0.21968 -0.35801 -0.03606 -0.24537 0.35481
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.22631 -0.35801 -0.03606 -0.24537 0.35481
Unusual Expense (Income) -0.686 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019
Total Current Assets 154.208 229.34 41.449 94.954
Cash and Short Term Investments 151.879 225.502 39.929 93.713
Cash & Equivalents 149.772 217.502 39.929 93.713
Total Receivables, Net 0.031 0.176 0.113 0.601
Accounts Receivable - Trade, Net 0.031 0.176 0.113 0.601
Prepaid Expenses 2.298 3.662 1.407 0.64
Total Assets 204.302 286.533 106.688 168.691
Property/Plant/Equipment, Total - Net 50.094 57.193 65.239 73.737
Property/Plant/Equipment, Total - Gross 76.275 77.633 79.5 82.154
Accumulated Depreciation, Total -26.181 -20.44 -14.261 -8.417
Other Long Term Assets, Total 0 0
Total Current Liabilities 19.58 11.05 11.233 10.842
Accounts Payable 1.595 2.094 2.274 3.272
Accrued Expenses 7.158 6.802 4.634 6.07
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 10.827 1.981 4.18 1.5
Other Current Liabilities, Total 0 0.173 0.145 0
Total Liabilities 87.374 164.359 36.016 36.49
Total Long Term Debt 39.189 48.47 23.912 24.819
Long Term Debt 20.336 27.361 0.822 0
Capital Lease Obligations 18.853 21.109 23.09 24.819
Deferred Income Tax 0 0.144 0
Other Liabilities, Total 28.605 104.839 0.727 0.829
Total Equity 116.928 122.174 70.672 132.201
Redeemable Preferred Stock 420.989 420.989
Common Stock 0.01 0.01 0.022 0.021
Additional Paid-In Capital 543.456 536.737 37.757 32.763
Retained Earnings (Accumulated Deficit) -426.538 -414.573 -388.096 -321.572
Total Liabilities & Shareholders’ Equity 204.302 286.533 106.688 168.691
Total Common Shares Outstanding 103.229 103.004 103.003 103.003
Short Term Investments 2.107 8
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 102.851 120.562 133.855 154.208 174.612
Cash and Short Term Investments 99.986 114.604 131.677 151.879 171.731
Cash & Equivalents 99.986 114.604 129.57 149.772 163.731
Total Receivables, Net 0 0 0 0.031 0.031
Accounts Receivable - Trade, Net 0 0 0 0.031 0.031
Prepaid Expenses 2.721 5.958 2.178 2.298 2.85
Total Assets 149.385 168.106 182.976 204.302 226.219
Property/Plant/Equipment, Total - Net 45.679 47.544 49.121 50.094 51.607
Property/Plant/Equipment, Total - Gross 75.927 76.477 76.86 76.275 76.599
Accumulated Depreciation, Total -30.248 -28.933 -27.739 -26.181 -24.992
Other Long Term Assets, Total 0.855
Total Current Liabilities 15.137 11.388 23.601 19.58 17.906
Accounts Payable 3.018 2.362 1.954 1.595 3.255
Accrued Expenses 9.638 6.622 6.461 7.158 8.007
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 2.481 2.404 15.186 10.827 6.471
Other Current Liabilities, Total 0 0.173
Total Liabilities 112.392 106.989 101.089 87.374 107.547
Total Long Term Debt 16.96 17.614 34.662 39.189 43.728
Long Term Debt 0 0 16.41 20.336 24.286
Capital Lease Obligations 16.96 17.614 18.252 18.853 19.442
Deferred Income Tax
Other Liabilities, Total 80.295 77.987 42.826 28.605 45.913
Total Equity 36.993 61.117 81.887 116.928 118.672
Redeemable Preferred Stock
Common Stock 0.01 0.01 0.01 0.01 0.01
Additional Paid-In Capital 549.191 547.32 545.384 543.456 541.48
Retained Earnings (Accumulated Deficit) -512.208 -486.213 -463.507 -426.538 -422.818
Total Liabilities & Shareholders’ Equity 149.385 168.106 182.976 204.302 226.219
Total Common Shares Outstanding 103.461 103.408 103.329 103.229 103.099
Short Term Investments 0 0 2.107 2.107 8
Other Current Assets, Total 0.144
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -11.965 -26.477 -66.524 -85.422
Cash From Operating Activities -71.129 -81.19 -55.568 -71.787
Cash From Operating Activities 8.21 8.241 8.351 6.749
Non-Cash Items -68.403 -62.397 4.974 4.588
Cash Interest Paid 2.668 1.123 0 0
Changes in Working Capital 1.029 -0.557 -2.369 2.298
Cash From Investing Activities 4.845 -8.22 -0.268 -8.125
Capital Expenditures -1.048 -0.22 -0.318 -8.125
Other Investing Cash Flow Items, Total 5.893 -8 0.05 0
Cash From Financing Activities -1.446 266.983 2.052 -0.074
Financing Cash Flow Items 0 -3.945 0 0
Issuance (Retirement) of Stock, Net 0.535 0.598 0.301 1.218
Issuance (Retirement) of Debt, Net -1.981 270.33 1.751 -1.292
Net Change in Cash -67.73 177.573 -53.784 -79.986
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -36.969 -11.965 -8.245 17.036 -19.832
Cash From Operating Activities -18.641 -71.129 -52.17 -35.366 -18.797
Cash From Operating Activities 2.073 8.21 6.096 4.061 2.04
Non-Cash Items 16.414 -68.403 -53.13 -56.087 -1.396
Cash Interest Paid 0.881 2.668 1.867 1.165 0.563
Changes in Working Capital -0.159 1.029 3.109 -0.376 0.391
Cash From Investing Activities -1.152 4.845 -0.367 -0.156 -0.022
Capital Expenditures -1.152 -1.048 -0.367 -0.156 -0.022
Cash From Financing Activities -0.409 -1.446 -1.234 -0.945 -0.461
Financing Cash Flow Items 0 0 0 0
Issuance (Retirement) of Stock, Net 0.119 0.535 0.229 0.012 0.001
Issuance (Retirement) of Debt, Net -0.528 -1.981 -1.463 -0.957 -0.462
Net Change in Cash -20.202 -67.73 -53.771 -36.467 -19.28
Other Investing Cash Flow Items, Total 5.893 0 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Humacyte, Inc. Company profile

About Humacyte Inc

Humacyte, Inc. (Humacyte), formerly Alpha Healthcare Acquisition Corp., is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. The Company uses its technology platform to engineer and manufacture human acellular vessels (HAVs). The HAVs are designed to be implanted into any patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio (or cabinet) of HAVs with varying diameters and lengths. The HAV cabinet offers treatment solution in various clinical areas within vascular repair, reconstruction and replacement market, including trauma, AV access for hemodialysis, peripheral arterial disease (PAD), and coronary artery bypass grafting (CABG). In addition, the Company develops HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Humacyte Inc revenues increased from $0K to $1.1M. Net loss applicable to common stockholders increased from $19K to $69.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items totaled to -$1.91.

Industry: Biotechnology & Medical Research (NEC)

2525 East North Carolina Highway 54
DURHAM
NORTH CAROLINA 27713
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,571.77 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

70,895.50 Price
+3.020% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading